COLL Stock Analysis: Collegium Pharmaceutical | NASDAQ
Drug Manufacturers - Specialty & Generic | NASDAQ, USA | Market Cap: 1.215m USD | 12M Return: 6.1% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 14.9M
EPS Trend: 63.6%
Qual. Beats: 1
Rev. Trend: 97.8%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Collegium Pharmaceutical, Inc. (NASDAQ: COLL) is a U.S.-based specialty pharmaceutical company headquartered in Stoughton, Massachusetts. Founded in 2002 and listed on the market since its 2015 IPO, the company focuses on developing and commercializing medicines primarily for pain management.
Its product portfolio includes Jornay PM for ADHD, Belbuca and Xtampza ER for severe chronic pain, Nucynta ER and IR formulations of tapentadol for acute and persistent pain, and Symproic for opioid-induced constipation. The inclusion of abuse-deterrent formulations such as Xtampza ER highlights a notable business model emphasis on addressing opioid safety alongside therapeutic efficacy.
- Xtampza ER and Belbuca sales growth drive pain franchise revenue
- Jornay PM gains share in competitive ADHD stimulant market
- Opioid litigation and DEA quota constraints pose regulatory headwinds
| Net Income: 74.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.20 > 0.02 and ΔFCF/TA 7.92 > 1.0 |
| NWC/Revenue: 39.02% < 20% (prev 6.15%; Δ 32.87% < -1%) |
| CFO/TA 0.20 > 3% & CFO 331.0m > Net Income 74.9m |
| Net Debt (391.5m) to EBITDA (609.9m): 0.64 < 3 |
| Current Ratio: 1.71 > 1.5 & < 3 |
| Outstanding Shares: last quarter (40.1m) vs 12m ago 22.00% < -2% |
| Gross Margin: 60.68% > 18% (prev 57.69%; Δ 2.99% > 0.5%) |
| Asset Turnover: 48.51% > 50% (prev 40.72%; Δ 7.79% > 0%) |
| Interest Coverage Ratio: 1.66 > 6 (EBIT TTM 271.1m / Interest Expense TTM 162.9m) |
| A: 0.19 (Total Current Assets 745.7m - Total Current Liabilities 435.0m) / Total Assets 1.65b |
| B: -0.05 (Retained Earnings -86.6m / Total Assets 1.65b) |
| C: 0.17 (EBIT TTM 271.1m / Avg Total Assets 1.64b) |
| D: 0.23 (Book Value of Equity 312.4m / Total Liabilities 1.34b) |
| Altman-Z'' = 2.42 = A |
| DSRI: 0.83 (Receivables 228.8m/228.7m, Revenue 796.3m/664.3m) |
| GMI: 0.95 (GM 57.69% / 60.68%) |
| AQI: 0.81 (AQ_t 0.54 / AQ_t-1 0.66) |
| SGI: 1.20 (Revenue 796.3m / 664.3m) |
| TATA: -0.16 (NI 74.9m - CFO 331.0m) / TA 1.65b) |
| Beneish M = -3.19 (Cap -4..+1) = AA |
As of July 14, 2026, the stock is trading at USD 34.82 with a total of 343,220 shares traded. Over the past week, the price has changed by -7.07%, over one month by +1.84%, over three months by -2.25% and over the past year by +6.06%.
Current recommended Stop Loss: 32.90 (which is 5.5% or 1.3 ATR below the current price).
Collegium Pharmaceutical has received a consensus analysts rating of 4.20. Therefore, it is recommended to buy COLL.
- StrongBuy: 2
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 54.3 | 56% |
P/E Trailing = 18.1893
P/E Forward = 4.985
P/S = 1.5261
P/B = 3.8442
Revenue TTM = 796.3m USD
EBIT TTM = 271.1m USD
EBITDA TTM = 609.9m USD
Long Term Debt = 770.2m USD (from longTermDebt, last quarter)
Short Term Debt = 34.1m USD (from shortTermDebt, last quarter)
Debt = 813.3m USD (from shortLongTermDebtTotal, last quarter) + Leases 5.24m
Net Debt = 391.5m USD (calculated: Debt 813.3m - CCE 421.8m)
Enterprise Value = 1.61b USD (1.22b + Debt 813.3m - CCE 421.8m)
Interest Coverage Ratio = 1.66 (Ebit TTM 271.1m / Interest Expense TTM 162.9m)
EV/FCF = 4.87x (Enterprise Value 1.61b / FCF TTM 329.8m)
FCF Yield = 20.53% (FCF TTM 329.8m / Enterprise Value 1.61b)
FCF Margin = 41.42% (FCF TTM 329.8m / Revenue TTM 796.3m)
Net Margin = 9.41% (Net Income TTM 74.9m / Revenue TTM 796.3m)
Gross Margin = 60.68% ((Revenue TTM 796.3m - Cost of Revenue TTM 313.2m) / Revenue TTM)
Gross Margin QoQ = 60.59% (prev 62.49%)
Tobins Q-Ratio = 0.97 (Enterprise Value 1.61b / Total Assets 1.65b)
Interest Expense / Debt = 20.03% (Interest Expense 162.9m / Debt 813.3m)
Taxrate = 30.75% (33.3m / 108.2m)
NOPAT = 187.7m (EBIT 271.1m * (1 - 30.75%))
Current Ratio = 1.71 (Total Current Assets 745.7m / Total Current Liabilities 435.0m)
Debt / Equity = 2.60 (Debt 813.3m / totalStockholderEquity, last quarter 312.4m)
Debt / EBITDA = 0.64 (Net Debt 391.5m / EBITDA 609.9m)
Debt / FCF = 1.19 (Net Debt 391.5m / FCF TTM 329.8m)
Total Stockholder Equity = 280.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.57% (Net Income 74.9m / Total Assets 1.65b)
RoE = 26.74% (Net Income TTM 74.9m / Total Stockholder Equity 280.3m)
RoCE = 25.81% (EBIT 271.1m / Capital Employed (Equity 280.3m + L.T.Debt 770.2m))
RoIC = 15.50% (NOPAT 187.7m / Invested Capital 1.21b)
WACC = 10.30% (E(1.22b)/V(2.03b) * Re(7.91%) + D(813.3m)/V(2.03b) * Rd(20.03%) * (1-Tc(0.31)))
Discount Rate = 7.91% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -31.71 | Cagr: -1.85%
[DCF] Terminal Value 71.93% ; FCFF base≈276.5m ; Y1≈317.0m ; Y5≈466.5m
[DCF] Fair Price = 148.9 (EV 5.22b - Net Debt 391.5m = Equity 4.83b / Shares 32.4m; r=10.30% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 63.60 | EPS CAGR: 13.05% | SUE: 1.42 | # QB: 1
Revenue Correlation: 97.81 | Revenue CAGR: 16.87% | SUE: 1.30 | # QB: 1
EPS current Quarter (2026-06-30): EPS=1.75 | Chg30d=+0.26% | Revisions=-12% | Analysts=3
EPS next Quarter (2026-09-30): EPS=2.08 | Chg30d=+7.51% | Revisions=+62% | Analysts=5
EPS current Year (2026-12-31): EPS=7.72 | Chg30d=+4.58% | Revisions=+38% | GrowthEPS=+4.0% | GrowthRev=+12.0%
EPS next Year (2027-12-31): EPS=7.61 | Chg30d=+26.11% | Revisions=+62% | GrowthEPS=-1.4% | GrowthRev=+1.3%
[Analyst] Revisions Ratio: +52% (up=16, down=4)